Research proramme: large serine recombinases - Seamless Therapeutics
Alternative Names: IntSTX-SH2; IntSTX-SH2 2.0Latest Information Update: 19 Nov 2024
Price :
$50 *
At a glance
- Originator Seamless Therapeutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified